DermaSensor Secures $4 Million in Series B Extension
DermaSensor, a company based in Miami, Florida, has successfully raised $4 million in a Series B Extension funding round. The company is known for its AI-powered device that aids physicians in detecting skin cancer at the point of care. This technology boasts a 96% sensitivity rate across the three most common types of skin cancer.
Leadership and Vision
Cody Simmons, CEO of DermaSensor, leads the company with a focus on integrating advanced AI technology into everyday medical practice to improve early detection of skin cancer. This funding round marks another step in their mission to make cancer detection more accessible and efficient.
Use of Funds
While specific plans for the newly acquired funds have not been detailed, it is expected that DermaSensor will use this capital to further develop its technology and expand its reach into more healthcare facilities. Enhancements in device accuracy and usability could also be potential areas of investment.
Funding and Investment Details
This Series B Extension round raised $4 million. Details about the investors involved in this round have not been disclosed.
DermaSensor's continued growth and development of its AI-driven medical device highlight the increasing importance of integrating technology into healthcare solutions. As the company progresses, it could play a significant role in enhancing the capabilities of healthcare providers in skin cancer detection.